发明授权
US09212149B2 Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors
有权
取代的2-氨基喹唑啉-4-酮作为基质金属蛋白酶-13抑制剂
- 专利标题: Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors
- 专利标题(中): 取代的2-氨基喹唑啉-4-酮作为基质金属蛋白酶-13抑制剂
-
申请号: US11579298申请日: 2005-04-28
-
公开(公告)号: US09212149B2公开(公告)日: 2015-12-15
- 发明人: Jun Terauchi , Hiroshi Nara , Hideyuki Oki , Kenjiro Sato
- 申请人: Jun Terauchi , Hiroshi Nara , Hideyuki Oki , Kenjiro Sato
- 申请人地址: JP Osaka-Shi
- 专利权人: Takeda Pharmaceutical Company Limited
- 当前专利权人: Takeda Pharmaceutical Company Limited
- 当前专利权人地址: JP Osaka-Shi
- 代理机构: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
- 代理商 David G. Conlin
- 优先权: JP2004-135596 20040430
- 国际申请: PCT/JP2005/008549 WO 20050428
- 国际公布: WO2005/105760 WO 20051110
- 主分类号: C07D239/90
- IPC分类号: C07D239/90 ; C07D487/04 ; C07D491/04 ; C07D495/04 ; C07D471/04 ; C07D217/26 ; C07D401/12 ; C07D405/12 ; C07D405/14 ; C07D409/14 ; C07D413/14
摘要:
The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen-containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5,6-dimethyl-4-oxo-1,4-dihadrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.
公开/授权文献
信息查询